CREATE medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license agreement with Monash University

CREATE-Monash-mRNA Victoria group shot. Credit Kelli Morris

01 August 2026

CREATE Medicines, Inc. (“CREATE”), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced a strategic research collaboration with Australia’s Monash University and its world-leading Monash Institute of Pharmaceutical Sciences (MIPS).

The partnership broadens CREATE’s portfolio by accessing Monash’s advanced lipid nanoparticle (LNP) technology including proprietary binders and chemistry, strengthening its leadership in developing best-in-class targeted in vivo therapies. Targeted delivery remains one of the primary challenges in realising the full therapeutic potential of in vivo cell therapies, requiring increasingly precise control over which immune cells receive therapeutic payloads.

Together, CREATE and MIPS will jointly advance targeted Chimeric Antigen Receptor (CAR) therapy, with the goal of enabling precise, cell-type-specific in vivo delivery of CAR payloads utilising the targeted LNP technology. Under the agreement, CREATE receives a worldwide exclusive license to all intellectual property, arising from the collaboration, together with the right to develop and commercialise CAR products directed to designated CAR targets. In turn, MIPS will receive research funding and downstream milestone and royalty payments.

The research at Monash will be led by a distinguished team of scientific experts. Professor Angus Johnston, a leading expert in nanoparticle delivery biology and intracellular trafficking, will serve as Principal Investigator. He will be supported by Professor Colin Pouton, and Dr Moore Chen, who co-authored a seminal 2025 Nature Nanotechnology paper pioneering a new method of delivering mRNA to target cells.

To read the full article, visit here.